Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency
<p>Abstract</p> <p>Background</p> <p>Subcutaneous immunoglobulin (SCIG) therapy is an alternative to intravenous immunoglobulin (IVIG) therapy.</p> <p>Methods</p> <p>We evaluated the efficacy and safety of the SCIG Vivaglobin<sup>® </sup...
Main Authors: | Hoffmann F, Grimbacher B, Thiel J, Peter HH, Belohradsky BH |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-06-01
|
Series: | European Journal of Medical Research |
Subjects: | |
Online Access: | http://www.eurjmedres.com/content/15/6/238 |
Similar Items
-
Ten-year population trends of immunoglobulin use, burden of adult antibody deficiency and feasibility of subcutaneous immunoglobulin (SCIg) replacement in Hong Kong Chinese
by: Andy Ka Chun Kan, et al.
Published: (2022-12-01) -
Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
by: Philipp Scheuerlein, et al.
Published: (2018-07-01) -
A clinician’s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases
by: Kristin Epland, et al.
Published: (2022-09-01) -
Immunoglobulin replacement therapies in inborn errors of immunity: a review
by: Archan Sil, et al.
Published: (2024-02-01) -
A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency
by: Andrea Visentin, et al.
Published: (2022-12-01)